An Observational Study of Patients With Dermatologic Disease (NCT07748169)
🩺 Plain-English Summary (8th-Grade Level)
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Who can join: Review the eligibility criteria below.
Location: Wake Forest University Health Science — Winston-Salem, North Carolina
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Wake Forest University Health Science — Winston-Salem, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
📞 Contact the Study Coordinator
Phone: (984) 234-0268
Email: lburch@pedestalhealth.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Vitiligo
- Daily Topical Rapamycin for Vitiligo — Charleston, South Carolina
- A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo — Glendale, Arizona
- A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo — Birmingham, Alabama
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Encinitas, California
- A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo — Scottsdale, Arizona
Explore by condition: All Vitiligo clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.